Tarsus Pharmaceuticals Inc Forecast, price target & analysts
Tarsus Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Tarsus Pharmaceuticals Inc Classifications & Recommendation:
Tarsus Pharmaceuticals Inc Price Target
| Target Price | $67.33 |
| Price | $43.55 |
| Potential |
54.61%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Tarsus Pharmaceuticals Inc 2026 .
The average Tarsus Pharmaceuticals Inc target price is $67.33.
This is
54.61%
register free of charge
$85.00
95.18%
register free of charge
$45.00
3.33%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Tarsus Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Tarsus Pharmaceuticals Inc stock has an average upside potential 2026 of
54.61%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 182.95 | 345.02 |
| 948.42% | 88.59% | |
| EBITDA Margin | -65.23% | -19.78% |
| 92.00% | 69.68% | |
| Net Margin | -64.35% | -21.65% |
| 93.66% | 66.36% |
7 Analysts have issued a sales forecast Tarsus Pharmaceuticals Inc 2025 . The average Tarsus Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Tarsus Pharmaceuticals Inc EBITDA forecast 2025. The average Tarsus Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Tarsus Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Tarsus Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.07 | -1.95 |
| 33.55% | 36.48% | |
| P/E | negative | |
| EV/Sales | 4.21 |
5 Analysts have issued a Tarsus Pharmaceuticals Inc forecast for earnings per share. The average Tarsus Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Tarsus Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Tarsus Pharmaceuticals Inc...
Current Tarsus Pharmaceuticals Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays | Locked ➜ Locked | Locked | Feb 26 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Feb 26 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 26 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Feb 24 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Feb 10 2025 |
| Barclays | Locked ➜ Locked | Locked | Jan 27 2025 |
| Oppenheimer | Locked ➜ Locked | Locked | Jan 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Feb 10 2025 |
|
Locked
Barclays: Locked ➜ Locked
|
Jan 27 2025 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Jan 22 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
